Forepont Capital Partners
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Forepont Capital Partners firmographics
Firmographics- Name
- Forepont Capital Partners
- Legal name
- Forepont Capital LLC
- Website
- https://forepont.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Forepont Capital Partners industry classification
Industry- Product category
- Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Debt Providers (FSANAAAL)
- akta.pro secondary industries
- Corporate Finance & Capital Advisory (BPAHADAB), Institutional Capital Introduction (LP/Family Office/Endowment Matching) (FSAEALAI)
Keywords
Where Forepont Capital Partners is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Forepont Capital Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others, Infrastructure
Distribution channels1 record
Marketing channels1 record
Forepont Capital Partners product offering
Product offeringCore offering
Forepont Capital Partners is a venture capital firm that invests early-stage capital in companies at the convergence of AI, nanotechnology, neuroscience, and biotechnology before their inflection points. The firm operates specialized funds — notably the Bio&Med Fund and the Brain AI Fund — and supports portfolio companies with board-level strategic, scientific, and technological guidance.
Product overview
Forepont Capital Partners is a venture capital firm that operates multiple specialized investment funds rather than offering a unified product platform. Their primary offerings include the Bio&Med Fund (targeting biotechnology and medical technology investments) and the Brain AI Fund (focused on AI-driven neuroscience and neurotechnology companies). The firm also identifies portfolio companies across diagnostics, precision medicine, neural interfaces, neurotech, braintech, AI applications in healthcare, medical devices, vaccines, and biopharmaceutical manufacturing technologies.
Differentiator
Problem solved
Functional benefit
Products and services
- Bio&Med Fund A venture capital fund focused on early-stage investments in biotechnology and medical technology companies before their inflection points, targeting improvements in life sciences and healthcare. Managed by Forepont Capital Partners.
- Brain AI Fund A specialized investment fund targeting artificial intelligence companies advancing neuroscience applications, including brain-computer interfaces, neurological treatments, and neurotech for healthcare, safety, education, defense, and device control.
Companies that use Forepont Capital Partners
Customer profileSegments1 record
Ideal customer profiles2 records
Forepont Capital Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Forepont Capital Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cooper PharmacoreMENA Partner in Dubai. Ayman Cheikh Lahlou is CEO of Cooper Pharma. The company has nine distribution centers and ten manufacturing sites across Morocco, Rwanda, the Ivory Coast, Spain, the Czech Republic, and Saudi Arabia. Manufacturing alliances with Merck, Pfizer, GSK, Abbott and Cipla.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Forepont Capital Partners competitors and assessment
Company assessmentDirect peers
- Lux Capital: Early-stage VC investing at the intersection of science, technology, and health with a heavy emphasis on AI/neuroscience/biotech convergence; the most directly comparable specialist peer to Forepont's Brain AI and Bio&Med thesis.
- Section 32: Venture firm founded by Bill Maris focused on technology, healthcare, and life sciences, including early-stage AI/biology convergence plays; closely comparable in mandate and stage to Forepont.
Broad incumbents
- Khosla Ventures: Large, science-and-tech focused venture firm with material exposure to AI, biotech, and neurotech; competes with Forepont for similar early-stage breakthrough science deals but at materially larger fund sizes.
- ARCH Venture Partners: Pioneer in early-stage science and biotech venture investing with comparable deep-tech, biotech, and neuroscience exposure; serves as a higher-scale benchmark for Forepont's Bio&Med strategy.
- Founders Fund: Prominent technology-focused venture firm with selective exposure to deep tech and biotech; competes with Forepont for early-stage founders in science-driven categories.
- Andreessen Horowitz (Bio + General): Diversified venture platform with dedicated bio/health fund and active AI investing; a leading scaled competitor for Forepont's convergence thesis deals.
- General Catalyst: Multi-stage venture investor with active health/bio and AI franchises; overlaps with Forepont's Brain AI and Bio&Med mandates and competes for similar early-stage deals.
- OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth, and public equities; comparable to Forepont's Bio&Med strategy for life-sciences and biotech early-stage deals.
- Bessemer Venture Partners: Long-standing multi-stage VC with deep healthcare and frontier-tech franchises; competes with Forepont for early-stage neurotech and biotech investments at larger check sizes.
- NEA (New Enterprise Associates): Large-scale, early-stage-focused venture firm with substantial healthcare and biotech franchises; a relevant scaled competitor for Forepont's early-stage biotech mandate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Forepont Capital Partners social profiles
Digital presenceForepont Capital Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Forepont Capital Partners leadership team
Management profileNumber of profiles
Profiles18 records
Forepont Capital Partners funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Forepont Capital Partners M&A and investment
M&A and investmentM&A
Investments18 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Forepont Capital Partners
What does Forepont Capital Partners do?
Forepont Capital Partners is a venture capital firm that invests early-stage capital in companies at the convergence of AI, nanotechnology, neuroscience, and biotechnology before their inflection points. The firm operates specialized funds — notably the Bio&Med Fund and the Brain AI Fund — and supports portfolio companies with board-level strategic, scientific, and technological guidance.
Is Forepont Capital Partners a public or private company?
Forepont Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Forepont Capital Partners founded?
Forepont Capital Partners was founded in 2017. It employs 11 to 50 people.
Where is Forepont Capital Partners based?
Forepont Capital Partners is headquartered in New York, United States, in the North America region.
Who are Forepont Capital Partners's main competitors?
Direct peers on record are Lux Capital and Section 32. Broad incumbents are Khosla Ventures, ARCH Venture Partners, Founders Fund, Andreessen Horowitz (Bio + General), General Catalyst, OrbiMed Advisors, Bessemer Venture Partners and NEA (New Enterprise Associates).
Does Forepont Capital Partners have an API?
No public API is recorded for Forepont Capital Partners.
What industry is Forepont Capital Partners in?
Forepont Capital Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAL, Venture Debt Providers, with a secondary code of BPAHADAB, Corporate Finance & Capital Advisory. Its NAICS code is 525 and its SIC code is 6282.